| Drug General Information |
| Drug ID |
D0P3HP
|
| Former ID |
DNC012674
|
| Drug Name |
1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H17N
|
| Canonical SMILES |
C1CC2CC3=CC=CC=C3CC2NC1
|
| InChI |
1S/C13H17N/c1-2-5-11-9-13-12(6-3-7-14-13)8-10(11)4-1/h1-2,4-5,12-14H,3,6-9H2
|
| InChIKey |
PXDWMPVOPNRION-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Integration of energy metabolism
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 1998 Oct 8;41(21):4165-70.N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. |
|---|
